Dr. Meghan Halley's lab at Stanford University explores the ethical dimensions of patient engagement in drug development for rare diseases. This research addresses the critical challenges and tensions that arise when patient and family groups collaborate with academic institutions and pharmaceutical companies to advance treatment options. By involving diverse stakeholders, the lab aims to create practical strategies for navigating ethical issues that impact research outcomes and enhance public trust in drug development processes.